Robert Zorc

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Ejection Fraction

Top Venues

Science (New York, N.Y.)

This page only lists publications with an associated author ORCID identifier.

Publications

Divij Mathew, Melina E Marmarelis, Caitlin Foley, Joshua M Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana W Davis, Maximillian Diehn, Josephine R Giles, Alexander C Huang, Wei-Ting Hwang, Nancy R Zhang, Adam J Schoenfeld, Erica L Carpenter, Corey J Langer, E John Wherry, Andy J Minn
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science (New York, N.Y.) 384 (6702) (2024)
Divij Mathew, Melina E Marmarelis, Caitlin Foley, Joshua M Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana W Davis, Maximillian Diehn, Josephine R Giles, Alexander C Huang, Wei-Ting Hwang, Nancy R Zhang, Adam J Schoenfeld, Erica L Carpenter, Corey J Langer, E John Wherry, Andy J Minn
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science (New York, N.Y.) 384 (6702) (2024)
Divij Mathew, Melina E Marmarelis, Caitlin Foley, Joshua M Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana W Davis, Maximillian Diehn, Josephine R Giles, Alexander C Huang, Wei-Ting Hwang, Nancy R Zhang, Adam J Schoenfeld, Erica L Carpenter, Corey J Langer, E John Wherry, Andy J Minn
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science (New York, N.Y.) 384 (6702) (2024)
Divij Mathew, Melina E Marmarelis, Caitlin Foley, Joshua M Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Christiana W Davis, Maximillian Diehn, Josephine R Giles, Alexander C Huang, Wei-Ting Hwang, Nancy R Zhang, Adam J Schoenfeld, Erica L Carpenter, Corey J Langer, E John Wherry, Andy J Minn
Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science (New York, N.Y.) 384 (6702) (2024)